Administrating docetaxel, doxorubicin, and cyclophosphamide as a neoadjuvant treatment may decrease lymphedema risk in breast cancer patients

Overview of attention for article published in Supportive Care in Cancer, February 2018

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (68th percentile)
Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

blogs: 1 blog

Readers on

mendeley: 7 Mendeley

So far, Altmetric has seen 1 blog post.

Administrating docetaxel, doxorubicin, and cyclophosphamide as a neoadjuvant treatment may decrease lymphedema risk in breast cancer patients

information for practice, 26 Apr 2018

Read the full article › The post Administrating docetaxel, doxorubicin, and cyclophosphamide as a neoadjuvant treatment may…